|
Toggle Summary
|
Positive Preclinical Data for KIN001 in wet Age-Related Macular Degeneration - Plans for Clinical Development
Positive Preclinical Data for KIN001 in wet Age-Related Macular Degeneration - Plans for Clinical Development
|
|
|
Toggle Summary
|
Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
|
|
|
Toggle Summary
|
Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA
Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA
|
|
|
Toggle Summary
|
Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19
Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19
|
|
|
Toggle Summary
|
Kinarus Announces Signing of a Transaction Agreement with Perfect Holding
Kinarus Announces Signing of a Transaction Agreement with Perfect Holding
|
|
|
Toggle Summary
|
Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines
Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines
|
|
|
Toggle Summary
|
Kinarus Secures CHF 57 Million Capital Commitment
Kinarus Secures CHF 57 Million Capital Commitment
|
|
|
Toggle Summary
|
Kinarus sind mehr als eine Wette auf ein Coronamittel
Kinarus sind mehr als eine Wette auf ein Coronamittel
|
|
|
Toggle Summary
|
Preclinical Data Confirm Triple Mechanism of Action of Lead Compound KIN001 in COVID-19
|
|
|
Toggle Summary
|
Signature of a Memorandum of Understanding with Perfect Holding SA
|
|
|
Toggle Summary
|
Big Pharma bring die Power, Startups liefern die Kreativität
Big Pharma bring die Power, Startups liefern die Kreativität
Big Pharma bringt die Power, Startups liefern die Kreativität
|
|
|
Toggle Summary
|
Unterschätzte Coronamedikamente
Unterschätzte Coronamedikamente
|
|
|
Toggle Summary
|
Kinarus further strengthens its leadership with two reputed industry experts
Hari Kumar, former CEO of Adheron Therapeutics, appointed Chairman of the Board of Directors and Thierry Fumeaux, MD, former member of Swiss National Covid Taskforce, appointed new Chief Medical Officer
|
|
|
Toggle Summary
|
First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study
Randomized, placebo-controlled Phase 2 study for Swiss biotech Kinarus’ orally administered lead candidate KIN001 in hospitalized COVID-19 patients.
|
|
|
Toggle Summary
|
Kinarus appoints Thierry Fumeaux, MD, as Chief Medical Officer
The current CMO Viktor Boerlin will stay with Kinarus and will support the portfolio as chief development advisor.
|
|
